Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN

Key Points

• Assenagon Asset Management bought 70,995 Repligen shares worth approximately $9.7 million, while institutional investors and hedge funds collectively own 97.64% of the company.
• Repligen exceeded quarterly expectations, reporting $0.54 in EPS versus the $0.45 consensus estimate and $204.13 million in revenue, up 11.9% year over year. The company expects fiscal 2026 EPS of $2.03–$2.09.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus rating and an average price target of $166.43; shares recently traded at $164.77, near their 52-week high.

Assenagon Asset Management S.A. bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 70,995 shares of the biotechnology company's stock, valued at approximately $9,687,000. Assenagon Asset Management S.A. owned approximately 0.13% of Repligen as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the 3rd quarter worth $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen in the fourth quarter worth about $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen in the fourth quarter worth approximately $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Repligen Stock Up 1.0%

RGEN opened at $164.77 on Wednesday. The company has a market capitalization of $9.30 billion, a PE ratio of 225.71, a price-to-earnings-growth ratio of 2.97 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The business has a 50-day moving average of $140.11 and a 200-day moving average of $131.05.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analysts' expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Royal Bank Of Canada assumed coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an "outperform" rating and a $160.00 price objective for the company. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, July 14th. Wolfe Research started coverage on Repligen in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 target price for the company. Finally, Zacks Research raised Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $166.43.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source